Double separate versus contiguous pituitary adenomas: MRI features and endocrinological follow up

Roberts, Sammie J; Borges, Manuel Thomas; Lillehei, Kevin O.; Kleinschmidt-DeMasters, B. K.

doi:10.1007/s11102-016-0727-0

Cited by 20 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our literature review, FGA co-occurring with lactotroph adenoma was not previously reported although our search generated 3 silent gonadotroph and lactotroph double adenoma cases ( Table 2 ). Roberts et al 7 presented 2 such cases; the first case was a 43-year-old woman who presented with amenorrhea and galactorrhea and had an elevated PRL level. Cabergoline treatment yielded a biochemical response without tumor size reduction.…”

Section: Discussionmentioning

confidence: 99%

“…Cabergoline treatment yielded a biochemical response without tumor size reduction. 7 The second case was a 56-year-old woman who presented with headaches. 7 Although the PRL level was not elevated, pathology reported an FSH/ASU staining–positive adenoma slightly intermingling with a PRL staining–positive adenoma.…”

Section: Discussionmentioning

confidence: 99%

“…5 , 6 Owing to the rarity of FGAs and double adenomas individually, reports of double pituitary adenomas containing an FGA are sparse. 7 , 8 , 9 , 10 , 11 We present a rare case of the co-occurrence of a gonadotroph adenoma and lactotroph adenoma.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Co-occurrence of Functional Gonadotroph Adenoma and Lactotroph Adenoma: A Case Report and Literature Review

Ullah¹,

Lopes²,

Jane³

et al. 2023

AACE Clinical Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Co-occurrence of Functional Gonadotroph Adenoma and Lactotroph Adenoma: A Case Report and Literature Review

Ullah¹,

Lopes²,

Jane³

et al. 2023

AACE Clinical Case Reports

View full text Add to dashboard Cite

“…d-f After transsphenoidal surgery, T1-weighted with contrast sagittal, T1-weighted without contrast coronal, T2-weighted without contrast coronal views, respectively, tumor resection collision sellar lesion can only be determined by histological examination; therefore, preoperative diagnosis is quite difficult. Most case reports include a pituitary adenoma coexisting with either neoplastic, adenomatous, congenital, vascular, or inflammatory sellar lesions such as: another adenoma [5,6,12,13]; craniopharyngioma [14][15][16][17][18]; schwannoma [5]; hypophysitis [19,20]; arachnoid, colloid, and epidermoid cysts [21][22][23]; gangliocytoma [5,[24][25][26]; Rathke's cleft cyst [5,14,27]; neurosarcoidosis [5,28]; plasmacytoma [29]; chondroma [30]; lymphoma [31]; lung cancer metastasis [32]; and meningioma [6][7][8].…”

Section: Discussionmentioning

confidence: 99%

Cushing’s disease due to a pituitary adenoma as a component of collision tumor: A case report and review of the literature

et al. 2020

View full text Add to dashboard Cite

Background: The coexistence of two morphologically different tumors attached to each other creates a very rare type of tumor called a collision tumor. Collision tumors containing pituitary adenoma-sellar meningioma have only been described in four cases to date; we discuss a fifth case harboring a collision tumor comprising a pituitary corticotroph adenoma and a sellar meningioma in the same anatomic position. Case presentation: A 34-year-old Caucasian woman presented with menstrual irregularity, severe weakness of the proximal muscles, and 10-15 kg weight gain within a year. Basal plasma cortisol and adrenocorticotrophic hormone levels were 17.7 mg/dL and 58 pg/mL, respectively. Her diurnal cortisol rhythm was impaired (plasma cortisol at 23: 00, 18.2 mg/dL) and after a 48-hour, 2-mg dexamethasone suppression test, plasma cortisol level was 13.6 mg/dL. The results were consistent with a diagnosis of Cushing's syndrome. We then performed a nocturnal 8-mg dexamethasone suppression test and the suppression of cortisol was not greater than 50% (21.4 to 19.3). A pituitary magnetic resonance imaging revealed a tuberculum sellae meningioma arising from within the sellar region. An operation was chosen in order to examine whether the tumor was an adrenocorticotrophic hormone/corticotropinreleasing hormone-secreting lesion or if there were any microadenomas that could be observed during the operation. Via an extended endoscopic endonasal approach the meningioma was resected successfully. Unexpectedly, our patient complained of nausea and vomiting postoperatively. Plasma cortisol was 2.6 mg/dL and orally administered hydrocortisone treatment was initiated immediately. Histopathological examination revealed that the tumor generally consisted of a pituitary corticotroph adenoma infiltrated by meningioma. Our patient maintained hydrocortisone treatment for 11 months. At the latest visit, she had lost 12 kg, and her hypertension, menstrual irregularity, and weakness of the proximal muscles had disappeared. Her mental and physical wellbeing were restored.

show abstract

“…Many reports of plurihormonal tumours have been a misinterpretation of either trapped non‐tumourous tissue or cross‐reactivities of antisera. A number of studies have reported double tumours arising in the adenohypophysis, and the use of transcription factors allows the clear distinction of these as separate lesions that should be distinguished from unusual plurihormonal neoplasms that would probably not respond to usual therapies. What remains to be shown is whether these are indicative of familial predisposition that is now recognized more widely in endocrine tumours, or whether they are simply a reflection of the common neoplastic triggers that remain unknown.…”

Section: Adenohypophysial Tumour Classification Based On Cytogenesismentioning

confidence: 99%

What's new in pituitary pathology?

Sylvia

Mete

2017

Histopathology

View full text Add to dashboard Cite

The increasing recognition of pituitary disorders and their impact on quality of life and longevity has made understanding of this small gland a subject of paramount importance. Pituitary pathology has seen many significant studies that indicate progress in identification and classification of pituitary lesions, as well as improved management strategies for patients. In this review, we outline six major areas of advances: (i) changes in terminology from 'adenoma' to 'pituitary neuroendocrine tumour'; (ii) reclassification of hormone-negative tumours based on transcription factor expression that defines lineage; (iii) updates in new pathogenetic mechanisms, including those that underlie rare lesions such as X-LAG and pituitary blastoma; (iv) clarification of hypophysitis due to immunotherapy, xanthomatous hypophysitis due to rupture of a Rathke's cleft cyst and IgG4 disease as the cause of inflammatory pseudotumour; (v) the consolidation of pituicytoma variants, including spindle cell oncocytoma and granular cell tumour based on thyroid transcription factor-1 (TTF-1) reactivity; and (vi) the pathogenetic mechanisms that distinguish papillary from adamantinomatous craniopharyngioma. The remaining challenge is clarification of the pathogenetic mechanisms underlying the development of many of these disorders.

show abstract

Double separate versus contiguous pituitary adenomas: MRI features and endocrinological follow up

Cited by 20 publications

References 20 publications

Co-occurrence of Functional Gonadotroph Adenoma and Lactotroph Adenoma: A Case Report and Literature Review

Co-occurrence of Functional Gonadotroph Adenoma and Lactotroph Adenoma: A Case Report and Literature Review

Cushing’s disease due to a pituitary adenoma as a component of collision tumor: A case report and review of the literature

What's new in pituitary pathology?

Contact Info

Product

Resources

About